Muhammad Hossein Ashoub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Hossein Ashoub has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Hajar Mardani Valandani
Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran
6 shared publications - Roohollah Mirzaee Khalilabadi
Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran
5 shared publications - Ahmad Fatemi
Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
3 shared publications - Ali Bazi
Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine Kerman University of Medical Sciences Kerman Iran
2 shared publications - Mahla Lashkari
Department of Chemistry, University at Albany, State University of New York, Albany, USA
2 shared publications - Ali Afgar
Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- 14 August 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43  (9) , 244
In vitro and in silico evaluation of the synergistic effect of Cytarabine and Zataria multiflora Boiss extract on pre-B acute lymphoblastic leukemia cells (NALM-6 cell line)
- 14 August 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43  (9) , 244
In vitro and in silico evaluation of the synergistic effect of Cytarabine and Zataria multiflora Boiss extract on pre-B acute lymphoblastic leukemia cells (NALM-6 cell line)
- 27 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53  (1) , 1278
Aptamer-mediated targeting of CXCR3-B in acute lymphoblastic leukemia nalm-6 cells: an in silico and in vitro study
- 27 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53  (1) , 1278
Aptamer-mediated targeting of CXCR3-B in acute lymphoblastic leukemia nalm-6 cells: an in silico and in vitro study
- 14 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52  (1) , 1-13
Zataria multiflora extract enhances imatinib-induced cytotoxicity in chronic myeloid leukemia and multiple myeloma cells
Background Zataria multiflora (ZM) is a medicinal plant with widespread antitumor effects. Tyrosine kinase inhibitors (TKIs) are considered the mainstay treatment in blood cancers; however, eventual resistance to TKIs poses a significant challenge in this area. The present study aimed to assess the synergistic effects of ZM extract (ZME) along with imatinib, a TKI, against K-562 and U-266 leukemic cell lines. Methods Cell viability was evaluated using the MTT assay, and apoptosis assessment was also conducted through Annexin-V/PI staining. Additionally, Real-Time PCR was used to assess the expression levels of BCR-ABL, P-TEN, c-MYC, Bax, and Bcl-2 genes. Molecular docking was carried out as an in-silico technique for both BCL-2 and ABL proteins. Results The results showed that both ZME and imatinib promoted apoptosis in K562 and U266 cells, with combination treatment significantly enhancing apoptotic cell death (e.g., 18.4% apoptosis in K562 cells with ZME + imatinib vs. 8.5% untreated; 46.9% in U266 cells vs. 11.6% untreated, P < 0.05). Combined treatment with imatinib and ZME upregulated the expression of Bax (5-fold in K562, 3-fold in U266) and P-TEN (2-fold in K562, 2.8-fold in U266) genes and downregulated the expression of Bcl-2 (0.3-fold in K562, 0.3-fold in U266), BCR-ABL (0.5-fold in K562), and c-MYC (0.4-fold in K562, 0.2-fold in U266) genes (P < 0.05). Molecular docking showed strong binding affinities between ZME constituents (carvacrol and thymol) and BCL-2 and ABL proteins. Conclusions ZME shows potential as a complementary agent in vitro, warranting further investigation.
- 14 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52  (1) , 1-13
Zataria multiflora extract enhances imatinib-induced cytotoxicity in chronic myeloid leukemia and multiple myeloma cells
Background Zataria multiflora (ZM) is a medicinal plant with widespread antitumor effects. Tyrosine kinase inhibitors (TKIs) are considered the mainstay treatment in blood cancers; however, eventual resistance to TKIs poses a significant challenge in this area. The present study aimed to assess the synergistic effects of ZM extract (ZME) along with imatinib, a TKI, against K-562 and U-266 leukemic cell lines. Methods Cell viability was evaluated using the MTT assay, and apoptosis assessment was also conducted through Annexin-V/PI staining. Additionally, Real-Time PCR was used to assess the expression levels of BCR-ABL, P-TEN, c-MYC, Bax, and Bcl-2 genes. Molecular docking was carried out as an in-silico technique for both BCL-2 and ABL proteins. Results The results showed that both ZME and imatinib promoted apoptosis in K562 and U266 cells, with combination treatment significantly enhancing apoptotic cell death (e.g., 18.4% apoptosis in K562 cells with ZME + imatinib vs. 8.5% untreated; 46.9% in U266 cells vs. 11.6% untreated, P < 0.05). Combined treatment with imatinib and ZME upregulated the expression of Bax (5-fold in K562, 3-fold in U266) and P-TEN (2-fold in K562, 2.8-fold in U266) genes and downregulated the expression of Bcl-2 (0.3-fold in K562, 0.3-fold in U266), BCR-ABL (0.5-fold in K562), and c-MYC (0.4-fold in K562, 0.2-fold in U266) genes (P < 0.05). Molecular docking showed strong binding affinities between ZME constituents (carvacrol and thymol) and BCL-2 and ABL proteins. Conclusions ZME shows potential as a complementary agent in vitro, warranting further investigation.
- Open Access
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-20
Microwave assisted solvothermal green synthesis of Fe3O4 nanoparticles using sea buckthorn for multiple myeloma and monocytic leukemia treatment
This study presents a microwave-solvothermal green synthesis of magnetite (Fe₃O₄) nanoparticles (NPs) using Hippophae rhamnoides berry extract and evaluates their selective anticancer activity. The NPs exhibited a crystalline structure (XRD peaks matching JCPDS Card No. 88–0315), superparamagnetic properties (VSM: saturation magnetization 40.32 emu/g), with a primary particle size of 15.6 nm (TEM) and a hydrodynamic diameter of 93.25 nm (DLS). FTIR confirmed surface functionalization, with Fe-O bands and organic groups indicating phytochemical adsorption. In vitro assays (MTT, BrdU, Annexin V-PI) on U266 (multiple myeloma), THP-1 (acute monocytic leukemia), and L-929 (normal fibroblast) cells showed dose- and time-dependent cytotoxicity, with U266 and THP-1 viability reduced to 15.3% and 14.2% at 150 µg/mL after 48 h, respectively, while L-929 viability remained at 86.9%. Flow cytometry revealed late apoptosis as the primary cell death mechanism (86.6% in U266, 66.5% in THP-1 at 150 µg/mL), driven by caspase-3 activation and oxidative stress (elevated TOS and MDA levels). These findings demonstrate the potential of these NPs as selective anticancer agents for hematological malignancies, supported by their physicochemical and biological properties.
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-20
Open AccessMicrowave assisted solvothermal green synthesis of Fe3O4 nanoparticles using sea buckthorn for multiple myeloma and monocytic leukemia treatment
This study presents a microwave-solvothermal green synthesis of magnetite (Fe₃O₄) nanoparticles (NPs) using Hippophae rhamnoides berry extract and evaluates their selective anticancer activity. The NPs exhibited a crystalline structure (XRD peaks matching JCPDS Card No. 88–0315), superparamagnetic properties (VSM: saturation magnetization 40.32 emu/g), with a primary particle size of 15.6 nm (TEM) and a hydrodynamic diameter of 93.25 nm (DLS). FTIR confirmed surface functionalization, with Fe-O bands and organic groups indicating phytochemical adsorption. In vitro assays (MTT, BrdU, Annexin V-PI) on U266 (multiple myeloma), THP-1 (acute monocytic leukemia), and L-929 (normal fibroblast) cells showed dose- and time-dependent cytotoxicity, with U266 and THP-1 viability reduced to 15.3% and 14.2% at 150 µg/mL after 48 h, respectively, while L-929 viability remained at 86.9%. Flow cytometry revealed late apoptosis as the primary cell death mechanism (86.6% in U266, 66.5% in THP-1 at 150 µg/mL), driven by caspase-3 activation and oxidative stress (elevated TOS and MDA levels). These findings demonstrate the potential of these NPs as selective anticancer agents for hematological malignancies, supported by their physicochemical and biological properties.
- 9 June 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42  (7) , 1-12
Dual-responsive magnetic and pH-sensitive hydrogel beads for controlled cisplatin delivery in glioblastoma cells
Glioblastoma (GB) is a highly aggressive brain tumor with poor prognosis due to its invasiveness and resistance to conventional therapies, necessitating advanced drug delivery systems to enhance treatment efficacy and reduce toxicity. This study aims to develop and evaluate dual-responsive magnetic and pH-sensitive beads for controlled cisplatin delivery to glioblastoma cell lines, addressing challenges in targeted therapy. Cobalt ferrite (CoFe2O4) nanoparticles were synthesized via a green co-precipitation method using clove extract as an alkalizing and stabilizing agent. These nanoparticles were incorporated into sodium alginate beads with cisplatin, cross-linked by Ca2+ ions. Beads were characterized using FTIR, XRD, SEM, and VSM. Swelling behavior, encapsulation efficiency, and in vitro drug release were assessed at pH 1.2 and 7.4, with and without a magnetic field. Cytotoxicity was evaluated via MTT assay on T98, A172, and L929 cell lines. The beads exhibited pH-dependent swelling, with maximum absorption at pH 7.4. Drug release was significantly enhanced under a 100 Hz magnetic field, achieving 70.2% cisplatin release in 80 min for CisB-4 beads. MTT assays demonstrated significant cytotoxicity against T98 and A172 cells (p < 0.05 to p < 0.0001), with minimal toxicity to normal L929 cells. These dual-responsive beads offer a promising platform for targeted cisplatin delivery in glioblastoma, with pH and magnetic field-mediated control, potentially improving therapeutic outcomes while minimizing systemic toxicity.
- 9 June 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42  (7) , 1-12
Dual-responsive magnetic and pH-sensitive hydrogel beads for controlled cisplatin delivery in glioblastoma cells
Glioblastoma (GB) is a highly aggressive brain tumor with poor prognosis due to its invasiveness and resistance to conventional therapies, necessitating advanced drug delivery systems to enhance treatment efficacy and reduce toxicity. This study aims to develop and evaluate dual-responsive magnetic and pH-sensitive beads for controlled cisplatin delivery to glioblastoma cell lines, addressing challenges in targeted therapy. Cobalt ferrite (CoFe2O4) nanoparticles were synthesized via a green co-precipitation method using clove extract as an alkalizing and stabilizing agent. These nanoparticles were incorporated into sodium alginate beads with cisplatin, cross-linked by Ca2+ ions. Beads were characterized using FTIR, XRD, SEM, and VSM. Swelling behavior, encapsulation efficiency, and in vitro drug release were assessed at pH 1.2 and 7.4, with and without a magnetic field. Cytotoxicity was evaluated via MTT assay on T98, A172, and L929 cell lines. The beads exhibited pH-dependent swelling, with maximum absorption at pH 7.4. Drug release was significantly enhanced under a 100 Hz magnetic field, achieving 70.2% cisplatin release in 80 min for CisB-4 beads. MTT assays demonstrated significant cytotoxicity against T98 and A172 cells (p < 0.05 to p < 0.0001), with minimal toxicity to normal L929 cells. These dual-responsive beads offer a promising platform for targeted cisplatin delivery in glioblastoma, with pH and magnetic field-mediated control, potentially improving therapeutic outcomes while minimizing systemic toxicity.
- 11 April 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114  (7) , 103792
pH-sensitive sulfasalazine release from green-synthesized mesoporous Fe3O4@SiO2 nanocomposites using Opuntia ficus-indica extract
- 11 April 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114  (7) , 103792
pH-sensitive sulfasalazine release from green-synthesized mesoporous Fe3O4@SiO2 nanocomposites using Opuntia ficus-indica extract
- 22 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51  (1) , 1-13
Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute lymphoblastic leukemia cells
Background Due to the high demand for novel approaches for leukemia-targeted therapy, this study investigates the impact of DNA-PK inhibitor NU7441 on the sensitivity of pre-B ALL cells to the telomerase inhibitor MST-312. Methods The study involved NALM-6 cells treated with MST-312 and NU7441, assessing their viability and metabolic activity using trypan blue and MTT assays. The study also evaluated apoptosis, gene expression changes, and DNA damage using flow cytometry, qRT-PCR, and micronucleus assays. The binding energy of MST-312 in the active site of telomerase was calculated using molecular docking. Results The study’s findings revealed a synergistic decline in both cell viability and metabolic activity in NALM-6 cells when exposed to the combined treatment of MST-312 and NU7441, and this decrease occurred without any adverse effects on healthy PBMC cells. Furthermore, the combination treatment exhibited a significantly higher induction of apoptosis than treatment with MST-312 alone, as observed through flow cytometry assay. qRT-PCR analysis revealed that this enhanced apoptosis was associated with a notable downregulation of Bcl-2 expression and an upregulation of Bax gene expression. Moreover, the combination therapy decreased expression levels of hTERT and c-Myc genes. The micronucleus assay indicated that the combination treatment increased DNA damage in NALM-6 cells. Also, a good conformation between MST-312 and the active site of telomerase was revealed by docking data. Conclusions The study suggests that simultaneous inhibition of telomerase and DNA-PK in pre-B ALL presents a novel targeted therapy approach.
- 22 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51  (1) , 1-13
Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute lymphoblastic leukemia cells
Background Due to the high demand for novel approaches for leukemia-targeted therapy, this study investigates the impact of DNA-PK inhibitor NU7441 on the sensitivity of pre-B ALL cells to the telomerase inhibitor MST-312. Methods The study involved NALM-6 cells treated with MST-312 and NU7441, assessing their viability and metabolic activity using trypan blue and MTT assays. The study also evaluated apoptosis, gene expression changes, and DNA damage using flow cytometry, qRT-PCR, and micronucleus assays. The binding energy of MST-312 in the active site of telomerase was calculated using molecular docking. Results The study’s findings revealed a synergistic decline in both cell viability and metabolic activity in NALM-6 cells when exposed to the combined treatment of MST-312 and NU7441, and this decrease occurred without any adverse effects on healthy PBMC cells. Furthermore, the combination treatment exhibited a significantly higher induction of apoptosis than treatment with MST-312 alone, as observed through flow cytometry assay. qRT-PCR analysis revealed that this enhanced apoptosis was associated with a notable downregulation of Bcl-2 expression and an upregulation of Bax gene expression. Moreover, the combination therapy decreased expression levels of hTERT and c-Myc genes. The micronucleus assay indicated that the combination treatment increased DNA damage in NALM-6 cells. Also, a good conformation between MST-312 and the active site of telomerase was revealed by docking data. Conclusions The study suggests that simultaneous inhibition of telomerase and DNA-PK in pre-B ALL presents a novel targeted therapy approach.
- 29 November 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62  (4) , 2796-2809
Differential Expression of the hTERT Gene in Umbilical Cord-Derived Mesenchymal Stem Cells Cocultured with B Cell Precursor Leukemia Cell Microparticles or CD41+/CD61+ Platelet Microparticles
- 29 November 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62  (4) , 2796-2809
Differential Expression of the hTERT Gene in Umbilical Cord-Derived Mesenchymal Stem Cells Cocultured with B Cell Precursor Leukemia Cell Microparticles or CD41+/CD61+ Platelet Microparticles
- 3 May 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102  (6) , 1301-1306
Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis
Ofatumumab’s therapeutic impact on patients with chronic lymphocytic leukemia (CLL) has been the subject of increasing clinical research. However, in recent years, no studies have yet provided a pooled assessment of the treatment effect of ofatumumab vs. non-ofatumumab regimens. Therefore, we conducted a progression meta-analysis to evaluate the efficacy of ofatumumab-based treatment in CLL patients using data from clinical studies. Relevant publications from PubMed, Web of Science and ClinicalTrials.gov were searched. The efficacy outcomes were progression-free survival (PFS) and overall survival (OS). The articles reviewed in the mentioned databases and matching the specified keywords were searched until January 2023. The pooled efficacy analysis showed that there was a significant difference in PFS [hazard ratios (HR) = 0.62, 95% confidence interval (CI) = 0.52–0.74] and no significant difference in OS (HR = 0.86, 95% CI = 0.71–1.03) between ofatumumab-based therapy and non-ofatumumab therapy. Our analysis showed the pooled efficacy for PFS was statistically significantly improved with ofatumumab-based treatments for CLL compared with other groups. Also, ofatumumab had no statistically significant improvement in the OS of patients with CLL. Thus, ofatumumab-based therapies for CLL patients could be improved by other combinational-based regimens.
- 3 May 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102  (6) , 1301-1306
Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis
Ofatumumab’s therapeutic impact on patients with chronic lymphocytic leukemia (CLL) has been the subject of increasing clinical research. However, in recent years, no studies have yet provided a pooled assessment of the treatment effect of ofatumumab vs. non-ofatumumab regimens. Therefore, we conducted a progression meta-analysis to evaluate the efficacy of ofatumumab-based treatment in CLL patients using data from clinical studies. Relevant publications from PubMed, Web of Science and ClinicalTrials.gov were searched. The efficacy outcomes were progression-free survival (PFS) and overall survival (OS). The articles reviewed in the mentioned databases and matching the specified keywords were searched until January 2023. The pooled efficacy analysis showed that there was a significant difference in PFS [hazard ratios (HR) = 0.62, 95% confidence interval (CI) = 0.52–0.74] and no significant difference in OS (HR = 0.86, 95% CI = 0.71–1.03) between ofatumumab-based therapy and non-ofatumumab therapy. Our analysis showed the pooled efficacy for PFS was statistically significantly improved with ofatumumab-based treatments for CLL compared with other groups. Also, ofatumumab had no statistically significant improvement in the OS of patients with CLL. Thus, ofatumumab-based therapies for CLL patients could be improved by other combinational-based regimens.
- 21 April 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479  (2) , 419-430
Extracellular microvesicles: biologic properties, biogenesis, and applications in leukemia
Microvesicles are cellular membrane vesicles of which size is limited to 30–1000 nm. Almost all cells release them in response to activation signals and apoptosis. Their ability for intercellular communication and enhancement of potential for information exchange (between them) has attracted much interest. Their content is affected by the content of the mother cell, which can help identify their origin. Furthermore, these particles can change the physiology of the target cells by transferring a set of molecules to them and changing the epigenetics of the cells by transferring DNA and RNA. These changes can be induced in cells close to the mother and distant cells. Significant activities of these microvesicles are known both in physiological and pathologic conditions. In this regard, we have reviewed these small particle elements, their contents, and the way of synthesis. Finally, we discussed their current known roles to reveal more potential applications in leukemia.
- 21 April 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479  (2) , 419-430
Extracellular microvesicles: biologic properties, biogenesis, and applications in leukemia
Microvesicles are cellular membrane vesicles of which size is limited to 30–1000 nm. Almost all cells release them in response to activation signals and apoptosis. Their ability for intercellular communication and enhancement of potential for information exchange (between them) has attracted much interest. Their content is affected by the content of the mother cell, which can help identify their origin. Furthermore, these particles can change the physiology of the target cells by transferring a set of molecules to them and changing the epigenetics of the cells by transferring DNA and RNA. These changes can be induced in cells close to the mother and distant cells. Significant activities of these microvesicles are known both in physiological and pathologic conditions. In this regard, we have reviewed these small particle elements, their contents, and the way of synthesis. Finally, we discussed their current known roles to reveal more potential applications in leukemia.